Adalimumab, a TNF-α inhibitor, secukinumab, an IL-17 inhibitor, and ustekinumab, which targets interleukin IL-12/23p40, are effective treatments for psoriasis and have shown potential in treating psoriasis concomitant with DM. The gene discussed is IL17A; the disease is dermatomyositis.